Published in J Clin Invest on January 01, 1985
Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of Apo A-I. J Clin Invest (1988) 1.07
Interaction between lymphocytes and platelets in the synthesis of prostacyclin. J Clin Invest (1987) 0.86
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature (1962) 18.89
Stimulation of endothelial cell prostacyclin production by thrombin, trypsin, and the ionophore A 23187. J Clin Invest (1978) 4.35
Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med (1982) 4.05
Localisation and stimulation of prostacyclin production in vascular cells. Nature (1978) 2.45
Accelerated prostacyclin degradation in the thrombotic thrombocytopenic purpura. Lancet (1981) 1.49
A NEW APPROACH TO STUDYING THE PROTEIN-BINDING PROPERTIES OF PENICILLINS. Nature (1963) 1.36
Metabolism of prostacyclin and 6-keto-prostaglandin F1 alpha in man. J Biol Chem (1980) 1.21
Presence of a platelet aggregating factor in the plasma of patients with thrombotic thrombocytopenic purpura (TTP) and its inhibition by normal plasma. Blood (1979) 1.15
Stability of prostacyclin in human plasma and whole blood: studies on the protective effect of albumin. Thromb Haemost (1981) 1.07
Stability of prostaglandin I2 in human blood. Prostaglandins (1981) 0.92
Albumins stabilize prostaglandin I2. Prostaglandins (1980) 0.91
Prostacyclin stabilising factor deficiency in thrombotic thrombocytopenic purpura. Lancet (1982) 0.90
Hemodialysis-exchange transfusion for treatment of thrombotic thrombocytopenic purpura. JAMA (1980) 0.89
Human plasma transforms prostacyclin (PGI2) into a platelet antiaggregatory substance which contracts isolated bovine coronary arteries. Prostaglandins (1980) 0.83
Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med (1993) 5.14
Poly(ethylenimine) and its role in gene delivery. J Control Release (1999) 3.78
Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation (1997) 3.27
Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost (1993) 3.12
Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery. Proc Natl Acad Sci U S A (1999) 2.81
Size matters: molecular weight affects the efficiency of poly(ethylenimine) as a gene delivery vehicle. J Biomed Mater Res (1999) 2.33
Adenovirus-mediated heme oxygenase-1 gene transfer inhibits the development of atherosclerosis in apolipoprotein E-deficient mice. Circulation (2001) 2.32
A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency. Lancet (1974) 2.29
Detailed alignment of saccharum and sorghum chromosomes: comparative organization of closely related diploid and polyploid genomes. Genetics (1998) 2.24
Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation (1999) 2.08
ARIC hemostasis study--I. Development of a blood collection and processing system suitable for multicenter hemostatic studies. Thromb Haemost (1989) 1.86
Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol (2001) 1.73
Identification of two point mutations and a one base deletion in exon 19 of the dystrophin gene by heteroduplex formation. Hum Mol Genet (1993) 1.67
Poly(ethylenimine)-mediated gene delivery affects endothelial cell function and viability. Biomaterials (2001) 1.65
Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc Natl Acad Sci U S A (1999) 1.60
Water immersion versus standard colonoscopy insertion technique: randomized trial shows promise for minimal sedation. Endoscopy (2010) 1.56
Poly(ethylenimine)-mediated transfection: a new paradigm for gene delivery. J Biomed Mater Res (2000) 1.50
Correlation of factor VIIa values with factor VII gene polymorphism, fasting and postprandial triglyceride levels, and subclinical carotid atherosclerosis. Circulation (1999) 1.49
Accelerated prostacyclin degradation in the thrombotic thrombocytopenic purpura. Lancet (1981) 1.49
Blood transfusion costs: a multicenter study. Transfusion (1991) 1.48
State of complementary and alternative medicine in cardiovascular, lung, and blood research: executive summary of a workshop. Circulation (2001) 1.47
Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochem Biophys Res Commun (1994) 1.44
The I1307K polymorphism of the APC gene in colorectal cancer. Gastroenterology (1999) 1.43
Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis (1991) 1.40
Improved packing of poly(ethylenimine)/DNA complexes increases transfection efficiency. Gene Ther (1999) 1.31
Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res (2001) 1.25
Deep vein thrombosis in spinal cord injury: effect of prophylaxis with calf compression, aspirin, and dipyridamole. Paraplegia (1982) 1.24
Metastatic tumors of the hand: a report of six cases. J Hand Surg Am (1978) 1.24
Sequential changes in factor VIII and platelets preceding deep vein thrombosis in patients with spinal cord injury. Br J Haematol (1980) 1.24
Endothelium-dependent contractions are associated with both augmented expression of prostaglandin H synthase-1 and hypersensitivity to prostaglandin H2 in the SHR aorta. Circ Res (1995) 1.20
Oral, inactivated, whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine: results of the initial evaluation in children. PRIDE Study Group. J Infect Dis (1999) 1.20
Increased platelet aggregates in patients with transient ischemic attacks. Stroke (1975) 1.20
Isozymes of pyruvate kinase in vertebrates: their physical, chemical, kinetic and immunological properties. Int J Biochem (1978) 1.18
Risk factors for the spread of HIV and other sexually transmitted infections among men who have sex with men infected with HIV in Lima, Peru. Sex Transm Infect (2008) 1.16
Factor VIII and other hemostasis variables are related to incident diabetes in adults. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care (1999) 1.16
A missense mutation in the dystrophin gene in a Duchenne muscular dystrophy patient. Nat Genet (1993) 1.15
Spectrum of small mutations in the dystrophin coding region. Am J Hum Genet (1995) 1.15
Aspirin and salicylate: An old remedy with a new twist. Circulation (2000) 1.15
Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clin Pharmacol Ther (2011) 1.15
Fallibility of the clinical diagnosis of venous thrombosis. JAMA (1975) 1.14
Some effects of artificial media upon glycolysis in rat platelets. Blood (1967) 1.13
Colocalization and interaction of cyclooxygenase-2 with caveolin-1 in human fibroblasts. J Biol Chem (2001) 1.12
Immune response, ciprofloxacin activity, and gender differences after human experimental challenge by two strains of enterotoxigenic Escherichia coli. Infect Immun (2006) 1.11
Cysteine 99 of endothelial nitric oxide synthase (NOS-III) is critical for tetrahydrobiopterin-dependent NOS-III stability and activity. Biochem Biophys Res Commun (1995) 1.10
Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb (1993) 1.08
Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Arterioscler Thromb (1993) 1.08
Spontaneous platelet aggregation in arterial insufficiency: mechanisms and implications. Thromb Haemost (1976) 1.06
Permeability of human endothelial monolayers: effect of vasoactive agonists and cAMP. J Appl Physiol (1985) (1989) 1.06
Cysteine 184 of endothelial nitric oxide synthase is involved in heme coordination and catalytic activity. J Biol Chem (1994) 1.06
Smoking cessation among Hong Kong Chinese smokers attending hospital as outpatients: impact of doctors' advice, successful quitting and intention to quit. Asia Pac J Public Health (2004) 1.06
Listeria monocytogenes L forms. I. Induction maintenance, and biological characteristics. J Bacteriol (1968) 1.05
Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation (1995) 1.05
Genotypic and phenotypic characterization of enterotoxigenic Escherichia coli strains isolated from Peruvian children. J Clin Microbiol (2010) 1.05
Influence of natural and recombinant interleukin 2 on endothelial cell arachidonate metabolism. Induction of de novo synthesis of prostaglandin H synthase. J Clin Invest (1988) 1.03
Metastatic tumors of the foot. South Med J (1978) 1.02
Predeposited autologous blood for elective surgery. A national multicenter study. N Engl J Med (1987) 1.01
The Common Rat as a Source of Erysipelothrix rhusiopathiae. Am J Public Health Nations Health (1947) 1.01
Colocalization of prostacyclin synthase with prostaglandin H synthase-1 (PGHS-1) but not phorbol ester-induced PGHS-2 in cultured endothelial cells. J Biol Chem (2000) 1.01
Platelet hyperaggregability and thrombosis in patients with thrombocythemia. Ann Intern Med (1978) 1.00
Endothelial nitric-oxide synthase. Evidence for bidomain structure and successful reconstitution of catalytic activity from two separate domains generated by a baculovirus expression system. J Biol Chem (1996) 1.00
Up-regulation of endothelial nitric-oxide synthase promoter by the phosphatidylinositol 3-kinase gamma /Janus kinase 2/MEK-1-dependent pathway. J Biol Chem (2001) 1.00
Sequential changes in coagulation and platelet function following femorotibial bypass. J Vasc Surg (1984) 1.00
Increased D allele frequency of the angiotensin-converting enzyme gene in pulmonary fibrosis. Hum Pathol (2001) 0.99
Factor VII-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bio-assay to activated factor VII: an international study. Thromb Haemost (1994) 0.98
Transcriptional induction of endothelial nitric oxide synthase type III by lysophosphatidylcholine. J Biol Chem (1995) 0.97
Characterization of the roles of the 594-645 region in human endothelial nitric-oxide synthase in regulating calmodulin binding and electron transfer. J Biol Chem (2000) 0.96
Distributions of hemostatic variables in blacks and whites: population reference values from the Atherosclerosis Risk in Communities (ARIC) Study. Ethn Dis (1992) 0.96
Platelet Pl(A2) allele and incidence of coronary heart disease: results from the Atherosclerosis Risk In Communities (ARIC) Study. Circulation (2000) 0.96
The effect of albumin upon the loss of enzymes from washed platelets. J Lab Clin Med (1972) 0.96
Thrombotic thrombocytopenic purpura. Survival following treatment with aspirin, dipyridamole, and prednisone. JAMA (1974) 0.96
Dystrophin expression in a Duchenne muscular dystrophy patient with a frame shift deletion. Neurology (1997) 0.96
Soluble thrombomodulin as predictor of incident coronary heart disease. Lancet (1999) 0.96
Detection of deep vein thrombosis with an automatic electrically calibrated strain gauge plethysmograph. Surgery (1977) 0.95
Activated microglia are the principal glial source of thromboxane in the central nervous system. Neurochem Int (1996) 0.95
Characterization of the promoter of human prostaglandin H synthase-1 gene. Biochem Biophys Res Commun (1993) 0.94
Molecular cloning and characterization of bovine prostacyclin synthase. Biochem Biophys Res Commun (1994) 0.94
Dopamine transporter DAT and receptor DRD2 variants affect risk of lethal cocaine abuse: a gene-gene-environment interaction. Transl Psychiatry (2013) 0.94
Flow cytometric studies of platelet responses to shear stress in whole blood. Biorheology (1995) 0.94
Mutation of Glu-361 in human endothelial nitric-oxide synthase selectively abolishes L-arginine binding without perturbing the behavior of heme and other redox centers. J Biol Chem (1997) 0.93
Shear-induced platelet aggregation in normal subjects and stroke patients. Thromb Haemost (1995) 0.93
A comparison of methods for the study of platelet hyperfunction in thromboembolic disorders. Br J Haematol (1980) 0.92
Cell cycle-dependent expression of cyclooxygenase-2 in human fibroblasts. FASEB J (2000) 0.91
Expression of prostaglandin H synthase (cyclooxygenase) in Hodgkin's mononuclear and Reed-Sternberg cells. Functional resemblance between H-RS cells and histiocytes or interdigitating reticulum cells. Am J Pathol (1988) 0.91
Relationship between types of surface shear stress profiles and membrane fouling. Water Res (2011) 0.91
Platelet activation in preeclampsia. Am J Obstet Gynecol (1985) 0.91
Stimulation of embryo hatching and implantation by prostacyclin and peroxisome proliferator-activated receptor delta activation: implication in IVF. Hum Reprod (2006) 0.91
Plasma fibrinogen and its correlates in Japanese and US population samples. Arterioscler Thromb (1993) 0.90
The effect of shear stress on the uptake and metabolism of arachidonic acid by human endothelial cells. Biochim Biophys Acta (1989) 0.90
Hybrids monosomal for human chromosome 5 reveal the presence of a spinal muscular atrophy (SMA) carrier with two SMN1 copies on one chromosome. Hum Genet (2001) 0.90
Primary structure of human thromboxane synthase determined from the cDNA sequence. J Biol Chem (1992) 0.90
Prostacyclin stabilising factor deficiency in thrombotic thrombocytopenic purpura. Lancet (1982) 0.90
Evidence for a proteolytic modification of liver pyruvate kinase in fasted rats. Arch Biochem Biophys (1979) 0.90
Induction of cyclooxygenase-2 in human umbilical vein endothelial cells by lysophosphatidylcholine. J Clin Invest (1995) 0.89
Extra-osseous chondrosarcoma. Report of five cases and review of the literature. J Bone Joint Surg Am (1980) 0.89
Plasma agouti-related protein level: a possible correlation with fasted and fed states in humans and rats. J Neuroendocrinol (2002) 0.89
Cyclooxygenase-2 induction in congestive heart failure: friend or foe? Circulation (1998) 0.89